title: [Incidence and management of ectopic pregnancy in Iceland 2000-2009].
abstract: Ectopic pregnancy can be life-threatening. Its treatment has changed radically during the last two decades. The study objective was to evaluate incidence and treatment of ectopic pregnancy in the Icelandic population during the decade 2000-2009.
  
  
  
  Information was collected about all diagnosed cases, place and method of treatment and admissions. The annual incidence was calculated with reference to number of pregnancies (n/1000), number of women aged 15-44 years (n/10 000) and by 5-year age groups, comparing the periods 2000-2004 and 2005-2009.
  
  
  
  The number of ectopic pregnancies during these 10 years was 836, or 444 during the years 2000-2004 and 392 during 2005-2009. The average annual incidence was 15.6/1000 pregnancies and 12.9/10 000 women. There was an annual incidence reduction from 17.3 to 14.1/1000 pregnancies (p<0.01) and 14.1 to 11.7/10 000 women (p<0.01). Surgery was the primary treatment for 94.9% of women, methotrexate in 3.2% and expectant management in 1.9%. Surgical management decreased from 98.0% to 91.3% between 5-year periods as medical treatment increased (0.4% to 6.4%; p<0.0001). The proportion of laparoscopic procedures increased from 80.5% to 91.1% (p<0.0001). In the university referral hospital this changed from 91.3% to 98.1% (p<0.001) and in rural hospitals from 44.0% to 69.3% (p<0.001). Mean hospital stay after open surgery was 3.2 days, but 0.9 days after laparoscopy.
  
  
  
  The incidence reduction of ectopic pregnancy is comparable to the development in neighbouring countries. Management has changed with increased use of laparoscopic surgery, medical and expectant treatment.
authors.forename: Áslaug
authors.initials: Á
authors.lastname: Baldvinsdottir
authors.forename: Jens A
authors.initials: JA
authors.lastname: Gudmundsson
authors.forename: Reynir Tómas
authors.initials: RT
authors.lastname: Geirsson
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D005260:Female; D006780:Hospitals, Rural; D006785:Hospitals, University; D006801:Humans; D007055:Iceland / Q000453:epidemiology; D015994:Incidence; D010535:Laparoscopy / Q000009:adverse effects; D007902:Length of Stay; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D013513:Obstetric Surgical Procedures / Q000009:adverse effects; D011247:Pregnancy; D011271:Pregnancy, Ectopic / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D012017:Referral and Consultation; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D008727:Methotrexate